CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 5 enrolled
Drug / intervention
11C-PBR28drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02702102
NCT02702102Phase 2Completed
CompareCT.gov

Imaging Inflammation in Patients With Diffuse Lewy Body Disease

Columbia University·interventional·Posted Mar 8, 2016·Updated Mar 18, 2025

In Brief

A Phase 2 clinical trial evaluating 11C-PBR28 for Diffuse Lewy Body Disease and 2 related conditions. Completed, enrolled 5 participants across 1 site.

Detailed Summary

This study uses a special type of scan called a positron emission tomography (PET) scan to take pictures of the brain. During the PET scan, a special dye called 11C-PBR28 is injected into the body. 11C-PBR28 sticks to parts of the brain where there is inflammation. The purpose of this study is to see if 11C-PBR28 can detect inflammation in patients with Parkinson's disease dementia or dementia with Lewy bodies. 11C-PBR28 is considered a drug by the Food and Drug Administration. 11C-PBR28 is not a treatment for any disease. Rather, 11C-PBR28 can be used to measure inflammation in the brain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Lewy Body Disease, Dementia With Lewy Bodies, Parkinson's Disease Dementia
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 8, 2016
Enrollment StartDec 1, 2015
Primary CompletionSep 4, 2019
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 10.3 years ago

Interventions

11C-PBR28drug

Up to 20 millicuries